Ezetimibe reduces urinary albumin excretion in hypercholesterolaemic type 2 diabetes patients with microalbuminuria

T. Nakamura, E. Sato, M. Amaha, Y. Kawagoe, S. Maeda, H. Inoue, S. I. Yamagishi

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)


Objective: This study investigated the effects of ezetimibe, an inhibitor of intestinal cholesterol absorption, on early phase diabetic nephropathy. Methods: A total of 32 hypercholesterolaemic type 2 diabetes patients with microalbuminuria, defined as a urinary albumin excretion (UAE) ≥ 30 but < 300 mg/g creatinine, were enrolled. Various clinical and laboratory parameters were determined at baseline and after 6 months of treatment with 10 mg/day ezetimibe. Results: Ezetimibe treatment significantly decreased glycated haemoglobin (HbA1c), low-density lipoprotein-cholesterol (LDL-C), triglycerides and UAE, and significantly increased high-density lipoprotein-cholesterol and albumin. It also decreased the serum level of monocyte chemoattractant protein-1 (MCP-1), but this difference was not statistically significant. Univariate analyses showed a correlation between UAE and body mass index, systolic and diastolic blood pressures, HbA1c, LDL-C, estimated glomerular filtration rate (inverse), creatinine and MCP-1. Since these parameters may be closely correlated with each other, multiple stepwise regression analysis was performed and demonstrated that HbA1c and MCP-1 were independent determinants of UAE. Conclusions: Ezetimibe may be a promising therapeutic strategy for improving albumin excretion, partly through its anti-inflammatory properties, and for reducing LDL-C in hypercholesterolaemic type 2 diabetes patients with microalbuminuria.

Original languageEnglish
Pages (from-to)798-803
Number of pages6
JournalJournal of International Medical Research
Issue number2
Publication statusPublished - 2012 Apr


  • Albuminuria
  • Diabetic nephropathy
  • Ezetimibe
  • Hypercholesterolaemia;monocyte chemoattractant protein-1

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Biochemistry, medical


Dive into the research topics of 'Ezetimibe reduces urinary albumin excretion in hypercholesterolaemic type 2 diabetes patients with microalbuminuria'. Together they form a unique fingerprint.

Cite this